Announcements Trials
Browse Landscape

Phase

Phase 2 53Phase 1 24Phase 1/2 15Phase 3 8Phase 2/3 2

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 1

Interventions

Cyclophosphamide 26Rituximab 17Etoposide 16Methotrexate 15Dexamethasone 15Cytarabine 15Vincristine 14Prednisone 11Doxorubicin 11Radiotherapy 10blinatumomab 8fludarabine 7Mercaptopurine 7Filgrastim 7Daunorubicin 7Asparaginase 7pegaspargase 6Granulocyte Colony-Stimulating Factor 6Methylprednisolone 5Drug Therapy 5Dasatinib 5venetoclax 4prednylidene 4etoposide phosphate 4deltacortene 4Trimethoprim, Sulfamethoxazole Drug Combination 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Busulfan 4Bendamustine Hydrochloride 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × CT-P10 × Lymphoid × Clear all
NCT03984448 2026-05-29

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
363 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡